Drug Profile
Research programme: sapphyrin-derived apoptosis inducers - Pharmacyclics
Alternative Names: PCI-2000; PCI-2022; PCI-2050; PCI-2051; PCI-2052; PCI-2053Latest Information Update: 16 Oct 2009
Price :
$50
*
At a glance
- Originator Pharmacyclics
- Class Porphyrins
- Mechanism of Action Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 19 Oct 2004 Data presented at the 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2004) have been added to the Cancer pharmacodynamics section
- 20 Apr 2004 Data presented at the 95th Annual Meeting of the American Association for Cancer Research (AACR-2004) have been added to the pharmacokinetics and Cancer pharmacodynamics sections
- 17 Dec 2003 Preclinical trials in Cancer in USA (IV)